Review of the scientific literature on drivers and barriers of seasonal influenza vaccination coverage in the EU/EEA
The report aims to provide a critical review of evidence on the barriers and drivers of seasonal influenza vaccination coverage in the EU/EEA. The report focuses on high-risk groups where high coverage of seasonal flu vaccination is most important. The 2009 Council of the European Union Recommendation on seasonal influenza vaccination encourages countries to implement measures that would increase seasonal influenza vaccination uptake to at least 75% for defined older age groups, and, if possible, for other risk groups. In support of this, the ECDC report summarises the evidence on what are the barriers and what are the drivers for seasonal influenza vaccination by each risk group
Report of the joint ECDC and WHO review of the national tuberculosis programme in Bulgaria
This report outlines the results of the joint ECDC and WHO review of the Bulgarian National Tuberculosis Control Programme.
Tuberculosis in Europe: from passive control to active elimination – high- and low-incidence countries
This four-page evidence brief provides an overview of tuberculosis control and elimination efforts in the EU/EEA, with a particular focus on the epidemiological differences between high- and low-incidence countries.
Guide to public health measures to reduce the impact of influenza pandemics in Europe – ‘The ECDC Menu’
This document presents a menu of possible public measures to be taken during influenza pandemics, giving public health and scientific information on what is known or can be said about their likely effectiveness, costs (direct and indirect), acceptability, public expectations and other more practical considerations. The ‘ECDC Menu’ aims to help EU Member States and institutions, individually or collectively, decide which measures they will apply.
Interim technical guidance on public health use of influenza antivirals during influenza pandemics
Antiviral drugs are an important addition to the public health arsenal against influenza. This interim guidance discusses the options for their effective use, especially during a pandemic.
Interim technical guidance on use of specific pandemic influenza vaccines during the H1N1 2009 pandemic
This interim guidance outlines the possible strategies that countries may wish to adopt in the deployment of a pandemic-specific vaccine, considering the two objectives of vaccination: protecting those at greatest risk of severe disease and maintaining essential services.
Interim ECDC public health guidance on case and contact management for the new influenza A(H1N1) virus infection
ECDC intends to produce a series of interim guidance documents on suggested procedures to be put in place in order to reduce the risk of transmission of the new influenza A(H1N1) virus. This guidance only applies to a situation when there are relatively few persons under investigation, and will be revised if there seems to be a wider spread.
Technical guidance on mitigation and delaying (or ‘containment’)strategies as the new influenza A(H1N1) virus comes into Europe
As epidemics of the new influenza A(H1N1) virus are extending globally, some European countries are considering how robustly to undertake case-finding among the first cases and whether to pursue and treat contacts.
The 2009 A(H1N1) pandemic in Europe, a review of the experience
This extended report aims to provide a broad overview of the epidemiology and virology of the 2009 pandemic in the European Union and European Economic Area countries. The main trends and information are derived from the analysis and interpretation of the epidemiological and virological data and other analyses provided to the European Centre for Disease Prevention and Control’s European Surveillance system through the European Influenza Surveillance Network.
ERLN-TB expert opinion on the use of the rapid molecular assays for the diagnosis of tuberculosis and detection of drug resistance
According to this report, the use of rapid molecular assays has diagnostic value in tuberculosis (TB) identification and detection of drug resistance, although there is not enough evidence to recommend these tools in all populations and situations and they should not replace standard diagnostic methods.